Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
Authors:
- 23 February 2024
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 41 (3) , 1-12
Abstract
Relapsed or refractory acute myeloid leukemia (AML) is associated with poor outcomes and resistance to therapy. The addition of venetoclax, a BCL-2 antagonist, to lower-intensity therapies results in improved survival in the first-line setting compared to monotherapy with a hypomethylating agent or low-dose cytarabine. Despite this, much remains unknown about the performance of venetoclax with a hypomethylating agent following the first-line setting. Additionally, while the ELN 2022 guidelines appear to improve the prognostication of AML, clarification is needed to determine how the revision applies to lower-intensity strategies. To investigate this, we retrospectively analyzed the performance of venetoclax with decitabine or azacitidine in relapsed or refractory AML under the ELN 2022 guidelines. We demonstrated that the ELN 2022 revision is not optimized for lower-intensity venetoclax-based strategies. To refine the prognostication schema, we showed significantly improved response and survival benefits for patients with mutated NPM1 and IDH. Relatively, patients with mutated NRAS, KRAS, and FLT3-ITD were associated with inferior response and survival. Furthermore, there is an unmet clinical need for tools to improve the selection of lower-intensity therapy candidates with borderline functional status. Using an incremental survival computation method, we discovered that a CCI score threshold of 5 distinguishes patients at an elevated risk of death. Together, these novel findings highlight areas of refinement to improve survival in relapsed or refractory AML.Keywords
All Related Versions
Funding Information
- Virginia Commonwealth University REDCap Grant (UL1TR002649)
- VCU Massey Cancer Center Biostatistics Shared Resource (P30 CA016059)
This publication has 25 references indexed in Scilit:
- Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemiaeJHaem, 2023
- Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid LeukemiaNew England Journal of Medicine, 2022
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapyBlood Cancer Journal, 2022
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AMLNew England Journal of Medicine, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Pathways and mechanisms of venetoclax resistanceLeukemia & Lymphoma, 2017
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994